Mettler-Toledo International, Inc. Stock 12‑Month Price Target Raised to $1544.42

JPMorgan raised its price target for Mettler-Toledo International to $1,550 from $1,400. The stock is currently trading at $1,598.03. Morgan Stanley also increased its target to $1,575 from $1,450.

Mettler-Toledo (MTD), a $25.9B diagnostics and research company, saw its stock reach a 52-week high of $1525.17 but has since fallen 15.1%. It outperformed the Nasdaq Composite over the past three months but lagged over the past year. MTD's Q2 2026 revenue was $1B, with adjusted EPS of $11.46, beating estimates. The company raised its full-year EPS guidance to $47.33. Analysts have a 'Moderate Buy' consensus rating with a mean price target of $1,464.60, implying 13.7% upside.

Redburn initiated coverage of Mettler-Toledo (MTD) with a Sell rating and a $1,200 price target, citing a premium valuation and modest growth outlook. The brokerage expects revenue to reach $4.25B in 2026 and $4.44B in 2027, with adjusted EPS of $47.29 and $51.40, respectively. Redburn highlights competition and pressure in China as concerns, despite the company's strong returns and market position.

Mettler-Toledo (MTD) reported Q2 2026 net sales of $1.027B, up 4% reported (6% local currency). Adjusted EPS was $11.46, up 14%. Adjusted operating margin was 29.3%. The company raised full-year 2026 guidance to 4% to 5% local currency revenue growth and adjusted EPS of $47.15 to $47.50, and plans $875M share repurchases.

Mettler-Toledo (MTD) reported Q2 revenue of $1.03B, matching analyst estimates, with 4.5% YoY growth. Adjusted EPS was $11.46 versus $10.81 expected, and operating margin rose to 30.6%. Management raised full-year Adjusted EPS guidance to $47.33 midpoint. Analysts focused on China demand, lab rebound durability, pricing, and biopharma/reshoring momentum.

Mettler-Toledo International (MTD) shares rose about 2.6% to around $1,416 after Q2 results beat expectations. Adjusted EPS was $11.46 on about $1.0b sales, with adjusted operating margin at 29.3%. The article also cites a valuation debate around a 31.6x trailing P/E versus DCF value.